Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Option, License and Collaboration Agreement entered into in 2020, giving Gilead an exclusive license to the anti-PD-1 program and option rights to clinical programs, with cost-sharing and royalties.
Investor Rights Agreement entered into in 2020, under which Gilead designated three individuals to the board of directors and a Science Committee was established.
Gilead acquired shares in the company's February 2025 underwritten equity offering from the underwriters.
Employment of a son of the CEO as Director in the chemistry department, with 2025 cash compensation, option and restricted stock unit grants.
Employment of another son of the CEO as Principal Investigator in the biology department, with 2025 cash compensation, option and restricted stock unit grants.
Employment of the CEO's daughter-in-law as Principal Investigator in the bioinformatics department, with 2025 cash compensation, option and restricted stock unit grants.
Loading...
